These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28116467)

  • 1. Intermittent catheterisation after botulinum toxin injections: the time to reassess our practice.
    Collins L; Sathiananthamoorthy S; Fader M; Malone-Lee J
    Int Urogynecol J; 2017 Sep; 28(9):1351-1356. PubMed ID: 28116467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder.
    Abrar M; Stroman L; Malde S; Solomon E; Sahai A
    Urology; 2020 Jan; 135():32-37. PubMed ID: 31626856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity.
    Faure Walker NA; Syed O; Malde S; Taylor C; Sahai A
    Urology; 2019 Jan; 123():242-246. PubMed ID: 30266377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
    Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
    Int Urogynecol J; 2017 Jun; 28(6):845-850. PubMed ID: 27889830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
    Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
    World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings.
    Kennelly M; Green L; Alvandi N; Wehbe S; Smith JJ; MacDiarmid S; Mangel J; Schwartz M; Aboushwareb T; Murray B
    Curr Med Res Opin; 2018 Oct; 34(10):1771-1776. PubMed ID: 29458265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
    Dowson C; Watkins J; Khan MS; Dasgupta P; Sahai A
    Eur Urol; 2012 Apr; 61(4):834-9. PubMed ID: 22204745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
    Patel DN; Jamnagerwalla J; Houman J; Anger JT; Eilber KS
    Int Urogynecol J; 2018 Jul; 29(7):1005-1009. PubMed ID: 28808734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention.
    Ghalayini IF; Al-Ghazo MA; Pickard RS
    BJU Int; 2005 Jul; 96(1):93-7. PubMed ID: 15963128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term compliance and results of intravesical botulinum toxin A injections in male patients.
    Rahnama'i MS; Marcelissen TAT; Brierley B; Schurch B; de Vries P
    Neurourol Urodyn; 2017 Sep; 36(7):1855-1859. PubMed ID: 28084637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
    Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
    BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
    Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
    Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review.
    Abrar M; Pindoria N; Malde S; Chancellor M; DeRidder D; Sahai A
    Eur Urol Focus; 2021 Nov; 7(6):1448-1467. PubMed ID: 32616412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
    Jiang YH; Ong HL; Kuo HC
    Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
    Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
    Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we define the optimal postvoid residual volume at which intermittent catheterization should be recommended, and are there other measures that could guide an intermittent catheterization protocol: ICI-RS 2023.
    Malde S; Belal M; Mohamed-Ahmed R; Gibson W; Padilla-Fernandez B; Rantell A; Selai C; Solomon E; Abrams P
    Neurourol Urodyn; 2024 Aug; 43(6):1353-1362. PubMed ID: 37905437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
    King AB; Rapp DE
    Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
    Mohee A; Khan A; Harris N; Eardley I
    BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.